DOI: http://dx.doi.org/10.18203/2349-3933.ijam20175134

Pseudocholinesterase, aspartate transaminase, alanine transaminase as markers for cervical cancer: a study in a tertiary care hospital

Vydehi Veeramalla

Abstract


Background: Cervical cancer is a malignant neoplasm arising from cells originating in the cervix, almost always caused by human papillomavirus (HPV). Butyrylcholinesterase is a non-specific cholinesterase enzyme that hydrolyses different choline esters. PCHE levels were lower than the normal at all the stages of cancer cervix. The present study was attempted to find out the role of some of the biochemical markers like serum pseudocholinesterase (PCHE), serum aspartate transaminase (AST), and serum alanine transaminase (ALT), in malignancy of the uterine cervix.

Methods: 60 patients aged between 30 -70 years who were having cervical cancer were included into the study and 30 healthy patients within the same age group were included as controls. 5ml of venous blood was collected from all the study participants under aseptic conditions in a plain tube. Serum Pseudocholinesterase, Serum Aspartate transaminase and Serum Alanine transaminase was estimated for all the patients in both the groups.

Results: The mean value of pseudocholinesterase in cervical cancer patients was lower in the cases when compared to controls and it was statistically significant (P value 0.0005), while the mean value of serum AST and ALT were higher in cases when compared to controls and it were also statistically significant. When compared with Pearson’s coefficient, the serum PChE had a significant negative correlation with AST and ALT, while the serum AST had a significant positive correlation with ALT and a negative correlation with PChE.

Conclusions: Among the women with cervical cancer, it was observed that the enzyme activity of PChE was lower than normal, while that of SGPT and SGOT were higher. PCHE, AST, and ALT can be used as tumor markers in the management of malignancy of the uterine cervix.


Keywords


Cervical cancer, Serum aspartate transaminase, Serum alanine transaminase, Serum pseudocholinesterase

Full Text:

PDF

References


Cervical Cancer Treatment (PDQ®)". NCI. 2014- 03-14. Archived from the original on 5 July 2014. Retrieved 24 June 2014 Available from: https://www.cancer.gov/types/cervical/patient/cervical-treatment-pdf.

Cervical Cancer Treatment (PDQ®)". National Cancer Institute. 2014-03-14. Retrieved 25 June 2014. Available form: https://www.ncbi. nlm.nih.gov/pubmedhealth/PMH0032580/.

Human Papillomavirus (HPV) Vaccines". National Cancer Institute. 2011-12-29. Retrieved 25 June 2014. Available form: https://www. cancer.gov/about-cancer/causesprevention/risk/ infectious-agents/hpv-vaccine-fact-sheet.

Tran NP, Hung CF, Roden R, Wu TC. Control of HPV infection and related cancer through vaccination. Recent Results Cancer Res. 2014;193:149-71.

Human Papillomavirus and Related Diseases Report. www.hpvcentre.net Available from: http://www.hpvcentre.net/statistics/reports/XWX.pdf.

Allderdice PW, Gardner HA, Galutira D, Lockridge O, LaDu BN, McAlpine PJ. "The cloned butyrylcholinesterase (BCHE) gene maps to a single chromosome site, 3q26.". Genomics. 1992;11(2): 452-4.

Chougule A, Hussain S, Agarwal DP. Prognostic and diagnostic value of serum pseudocholinesterase, serum aspartate transaminase, and serum alinine transaminase in malignancies treated by radiotherapy. J Can Res Ther. 2008;4:21-5.

Santarpia L, Grandoneet I. Butyrylcholinesterase as a prognostic marker: a review of the literature. J Cachexia Sarcopenia Muscle. 2013;4:31-9.

Fuhrman MP, Charney P, Mueller CM. Hepatic proteins and nutrition assessment. J Am Diet Assoc. 2004;104:1258-64.

Shan-Zhi G. Alterations of serum cholinesterase in patients with gastric cancer. World J Gastrenterol. 2005;11:4604-6.

Ogunkeye OO, Roluga AI. Serum cholinesterase activity helps to distinguish between liver disease and non liver disease aberration in liver function tests. Pathophysiol. 2006;13:91-3.

Singh TD, Barbhuiya MA, Poojary S, Shrivastav BR1, Tiwari PK. The liver function test enzymes and glucose level are positively correlated in gallbladder cancer: A cancer registry data analysis from north central India. Ind J Cancer. 2012;49:125-36.

Diehl AM, Potter J, Boitnott J, Van Duyn MA, Herlong HF, Mezey E. Relationship between pyridoxal 5-'phosphate deficiency and aminotransferase levels in alcoholic hepatitis. Gastroenterol, 1984;86:632-6.

Kathryn MF, Dow C, Michael M. Part I: Liver function in oncology: biochemistry and beyond. Lancet Oncol. 2008;9:1092-101.

Moss DW, Henderson R. Clinical Enzymology. Chapter 22, Tietz Text Book of Clinical Chemistry, 3rd ed. Philadelphia, WB Saunders; 1999.

Thriveni K, Rani James et al. Serum Transaminases Ratio in Breast Cancer Patients. Austral - Asian J Cancer. 2009;8(4):207-9.

Walboomers JM, Jacobs MV, Manos MM. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-9.

Mayrand MH, Duarte-Franco E, Rodrigues I, et al; Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357:1579-88.

McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: A retrospective cohort study. Lancet Oncol. 2008;9:425-34.

Benedet JL, Bender H, Jones H. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynaecol Obstet. 2000;70:209-62.

Bradamante V. Plasma Cholinesterase Activity in Patients with Uterine Cervical Cancer during Radiotherapy .Coll Antropol. 2000;24(2):373-80.

Oropollo AT. Abnormal pseudocholinesterase levels in a surgical population. Anaesthesiol. 1978;48:284.

Santarpia L, Alfonsi L, Pasanisi F, De Caprio C, Scalfi L, and Contaldo F, “Predictive factors of survival in patients with peritoneal carcinomatosis on home parenteral nutrition. ”Nutrition. 2006;22(4):355-60.

Vento S, Nobili V. Aminotransferases as predictors of mortality. The lancet. 2008;371:1822-3.

Rathinasabapathy R, and Zammit C. Preoperative abnormal Liver Function Tests (LFTs) in asymptomatic patients undergoing surgery for invasive breast cancer - is it worthwhile investigating further? European J Surg Oncol. 2010;36(11):1112-3.

Barbhuiya MA, Singh TD, Gupta S, Shrivastav BR, Tiwari PK. Incidence of gall bladder cancer in rural and semi urban population of north-central India. A first insight. Internet J Epidemiol. 2009;7:2.

Kontturi M, Sotaniemi E. Effect of Oestrogen on Liver Function of Prostatic Cancer Patients. Br Med J. 1969;4:204-5.

Tritz DB, Doll DC, Ringenberg QS, Anderson S, Madsen R, Perry MC, et al. Bone marrow involvement in small cell Lung cancer clinical significance and correlation with Cancer 1989;63:763-6.

Hui-Ju Tsai, Ming-Yen Hsieh. Liver function tests may be useful tools for advanced cancer patient care: A preliminary single-center result. Kaohsiung J Medic Sci. 2014;30:146-52.